SPDR S&P Pharmaceuticals ETF Rating $45.54 +0.03 (+0.07%) (As of 11:15 AM ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings SPDR S&P Pharmaceuticals ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XPH Aggregate RatingModerate Buy 2.70Holdings in XPH have an aggregate rating of Moderate Buy based on 363 analyst ratings issued in the past year covering 45 companies (99.9% of the portfolio).XPH Aggregate Price Target$45.54High Prediction$45.54Average Prediction$45.54Low Prediction$45.54Holdings in XPH have an aggregate price target of $45.54 and a range of $45.54 to $45.54 covering 45 companies (99.9% of the portfolio).XPH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 45 XPH Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.78%CORTCorcept Therapeutics$56.39+0.5%4.7045 of 5 stars3.00$65.25 15.7%5Positive News4.03%ITCIIntra-Cellular Therapies$85.01-0.7%4.4737 of 5 stars2.85$97.23 14.4%13Positive News4.01%LBPHLongboard Pharmaceuticals$59.760.0%1.4731 of 5 stars2.44$59.56 -0.3%93.79%VTRSViatris$13.16+0.2%1.3514 of 5 stars2.00$13.33 1.3%33.74%BMYBristol-Myers Squibb$57.884.7873 of 5 stars2.20$54.07 -6.6%20Analyst Revision3.67%JAZZJazz Pharmaceuticals$122.52+2.8%4.9183 of 5 stars2.80$175.33 43.1%15Analyst ForecastGap Up3.59%EWTXEdgewise Therapeutics$32.26+1.0%1.7413 of 5 stars3.00$38.40 19.0%53.37%CTLTCatalent$59.52+0.9%3.0395 of 5 stars2.00$63.40 6.5%73.36%ELANElanco Animal Health$13.36-0.6%4.1237 of 5 stars2.43$17.14 28.3%73.26%PRGOPerrigo$26.93-0.8%4.9834 of 5 stars2.75$37.00 37.4%4News CoveragePositive News3.25%AXSMAxsome Therapeutics$94.73+0.1%4.6663 of 5 stars3.00$124.93 31.9%14Analyst Upgrade3.21%RPRXRoyalty Pharma$26.52+1.1%4.7328 of 5 stars2.83$41.67 57.1%63.18%JNJJohnson & Johnson$154.46+0.9%4.9639 of 5 stars2.53$175.94 13.9%15Positive News3.15%PFEPfizer$24.92-0.1%5 of 5 stars2.50$32.92 32.1%16Analyst DowngradeAnalyst RevisionNews Coverage3.06%ZTSZoetis$176.24+0.3%4.8598 of 5 stars3.10$221.44 25.6%10Positive News2.93%MRKMerck & Co., Inc.$98.22+0.8%4.9964 of 5 stars2.68$130.86 33.2%19Dividend IncreasePositive News2.90%LLYEli Lilly and Company$740.17-1.8%4.9913 of 5 stars2.81$1,007.94 36.2%21Analyst Revision2.74%TARSTarsus Pharmaceuticals$46.08-1.1%1.8691 of 5 stars3.00$54.20 17.6%7Analyst Revision2.74%ARVNArvinas$23.63+4.1%3.0807 of 5 stars2.93$61.08 158.5%14Analyst ForecastShort Interest ↓News Coverage2.64%OGNOrganon & Co.$14.85+0.8%4.7298 of 5 stars2.50$21.33 43.7%42.42%SAVACassava Sciences$28.27+8.5%3.8449 of 5 stars3.00$111.50 294.4%22.35%PBHPrestige Consumer Healthcare$83.67+1.2%3.6888 of 5 stars2.67$83.67 0.0%32.11%SUPNSupernus Pharmaceuticals$35.75-1.0%2.3422 of 5 stars2.50$36.00 0.7%2Positive News2.01%PCRXPacira BioSciences$17.37+2.0%3.9929 of 5 stars2.20$23.50 35.3%10Positive News2.01%AMPHAmphastar Pharmaceuticals$44.15+0.1%4.7262 of 5 stars2.67$63.00 42.7%31.94%LGNDLigand Pharmaceuticals$116.76+4.7%4.9545 of 5 stars3.00$144.83 24.0%61.65%COLLCollegium Pharmaceutical$30.64+2.1%3.9752 of 5 stars2.60$42.60 39.0%51.52%OCULOcular Therapeutix$8.55-2.6%3.7464 of 5 stars2.86$16.71 95.5%71.49%ANIPANI Pharmaceuticals$55.44+0.6%4.3361 of 5 stars2.83$77.33 39.5%6Positive News1.33%HROWHarrow$43.64+2.8%3.7561 of 5 stars3.00$56.67 29.9%31.25%HRMYHarmony Biosciences$32.71-0.2%4.7919 of 5 stars2.56$47.00 43.7%91.24%AMRXAmneal Pharmaceuticals$8.34-0.8%3.211 of 5 stars2.80$10.00 19.9%5Insider Trade1.12%WVEWave Life Sciences$14.84+4.1%4.857 of 5 stars3.00$22.22 49.7%10Analyst ForecastAnalyst Revision1.07%MNMDMind Medicine (MindMed)$7.09-5.7%2.4201 of 5 stars3.25$25.38 257.9%121.01%EYPTEyePoint Pharmaceuticals$8.68-3.0%2.2894 of 5 stars3.00$28.00 222.6%91.00%PLRXPliant Therapeutics$13.04+2.4%3.4847 of 5 stars3.11$40.57 211.1%90.99%INVAInnoviva$19.16+0.1%1.2975 of 5 stars3.001News Coverage0.96%PHATPhathom Pharmaceuticals$9.26+6.1%2.3252 of 5 stars2.75$22.50 143.0%40.94%LQDALiquidia$10.15+0.3%3.7431 of 5 stars2.90$24.00 136.5%10Analyst Revision0.87%NMRANeumora Therapeutics$9.791.5781 of 5 stars2.71$21.67 121.3%70.86%FULCFulcrum Therapeutics$3.04+1.7%3.5645 of 5 stars2.20$9.33 207.0%10Analyst RevisionNews Coverage0.72%ELVNEnliven Therapeutics$25.39-0.2%2.3739 of 5 stars3.25$37.00 45.7%40.61%EOLSEvolus$12.77+1.1%4.0358 of 5 stars3.00$23.00 80.1%4Positive News0.53%NUVBNuvation Bio$2.65+2.7%2.3313 of 5 stars3.00$6.60 149.1%50.49%XERSXeris Biopharma$3.08+0.7%3.9457 of 5 stars2.67$4.87 58.0%3 This page (NYSEARCA:XPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
